PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31582211-0	2019	Treatment with metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9.	Metformin	15-24	urothelial cancer associated 1	Homo sapiens	134-138	
35316895-0	2022	The UCA1 and microRNA-18a signaling pathway mediates the irisin-lowering effect of metformin in the management of polycystic ovary syndrome.	Metformin	83-92	urothelial cancer associated 1	Homo sapiens	4-8	
32523353-0	2020	Metformin Suppresses the Proliferation and Promotes the Apoptosis of Colon Cancer Cells Through Inhibiting the Expression of Long Noncoding RNA-UCA1.	Metformin	0-9	urothelial cancer associated 1	Homo sapiens	144-148	
32523353-9	2020	Suppressing UCA1 expression by siRNA or shRNA could further enhance the metformin-mediated anticancer effects against colon cancer in vitro and in vivo.	Metformin	72-81	urothelial cancer associated 1	Homo sapiens	12-16	
32523353-10	2020	Metformin decreased the UCA1 expression and further inhibited the proliferation and promoted the apoptosis of the colon cancer cells, which were associated with inactivation of the PI3K/AKT and ERK signaling pathways in vitro and in the tumor tissues obtained from the mice.	Metformin	0-9	urothelial cancer associated 1	Homo sapiens	24-28	
32523353-11	2020	Conclusion: These results indicated that metformin has potential anticancer properties and revealed the anticancer mechanisms of metformin against colon cancer via regulating lncRNA-UCA1.	Metformin	41-50	urothelial cancer associated 1	Homo sapiens	182-186	
32523353-11	2020	Conclusion: These results indicated that metformin has potential anticancer properties and revealed the anticancer mechanisms of metformin against colon cancer via regulating lncRNA-UCA1.	Metformin	129-138	urothelial cancer associated 1	Homo sapiens	182-186	
31894313-0	2020	Metformin alleviates endometrial hyperplasia through the UCA1/miR-144/TGF-beta1/AKT signaling pathway.	Metformin	0-9	urothelial cancer associated 1	Homo sapiens	57-61	
31894313-2	2020	Reverse transcription-quantitative polymerase chain reaction, western blot and immunohistochemistry (IHC) assays were used to study the effects of Met and tamoxifen on the expression levels of urothelial cancer associated 1 (UCA1), microRNA-144 (miR-144) and other factors along the transforming growth factor-beta1 (TGF-beta1)/protein kinase B (AKT) signaling pathway.	Metformin	147-150	urothelial cancer associated 1	Homo sapiens	193-223	
31894313-2	2020	Reverse transcription-quantitative polymerase chain reaction, western blot and immunohistochemistry (IHC) assays were used to study the effects of Met and tamoxifen on the expression levels of urothelial cancer associated 1 (UCA1), microRNA-144 (miR-144) and other factors along the transforming growth factor-beta1 (TGF-beta1)/protein kinase B (AKT) signaling pathway.	Metformin	147-150	urothelial cancer associated 1	Homo sapiens	225-229	
31894313-6	2020	By contrast, Met reduced cell viability, promoted cell apoptosis, and reduced the expression levels of UCA1, TGF-beta and p-AKT, while upregulating the expression of miR-144 and active Caspase-3 in a dose-dependent manner.	Metformin	13-16	urothelial cancer associated 1	Homo sapiens	103-107	
31894313-11	2020	In conclusion, the current study suggested that Met reduces the risk of EH by reducing the expression levels of UCA1, TGF-beta and p-AKT, while increasing the levels of miR-144 and active Caspase-3 in a dose-dependent manner.	Metformin	48-51	urothelial cancer associated 1	Homo sapiens	112-116	
31582211-9	2019	Taken together, we found that administration of metformin prevents pre-eclampsia by suppressing migration of trophoblast cells via modulating the signaling pathway of UCA1/miR-204/MMP-9.	Metformin	48-57	urothelial cancer associated 1	Homo sapiens	167-171	
31582211-2	2019	This study aims to investigate the molecular mechanism of how UCA1 interferes with MMP9 expression under the influence of metformin, which contributes to the development of pre-eclampsia.	Metformin	122-131	urothelial cancer associated 1	Homo sapiens	62-66	
28641488-8	2017	Metformin downregulated both endogenous and exogenous UCA1 expression, leading to the inhibition of mammalian target of rapamycin-signal transducer and activator of transcription 3-hexokinase 2 signaling pathway.	Metformin	0-9	urothelial cancer associated 1	Homo sapiens	54-58	
28641488-9	2017	Our study provided the first evidence that metformin inhibited proliferation and glycolysis in cancer cells through regulation of long non-coding RNA UCA1.	Metformin	43-52	urothelial cancer associated 1	Homo sapiens	150-154